BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Harding JJ. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. Future Oncol 2018;14:2293-302. [PMID: 29663837 DOI: 10.2217/fon-2018-0008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Cho CS. Radiomics: A Well-Intentioned Leap of Faith. Ann Surg Oncol 2019;26:4178-9. [PMID: 31520206 DOI: 10.1245/s10434-019-07818-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:396. [PMID: 31500650 DOI: 10.1186/s13046-019-1396-4] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 25.3] [Reference Citation Analysis]
3 Chen H, Jia W. Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. Genes Dis 2020;7:320-7. [PMID: 32884986 DOI: 10.1016/j.gendis.2020.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cassol F, Portal L, Richelme S, Dupont M, Boursier Y, Arechederra M, Auphan-Anezin N, Chasson L, Laprie C, Fernandez S, Balasse L, Lamballe F, Dono R, Guillet B, Lawrence T, Morel C, Maina F. Tracking Dynamics of Spontaneous Tumors in Mice Using Photon-Counting Computed Tomography. iScience 2019;21:68-83. [PMID: 31655257 DOI: 10.1016/j.isci.2019.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Azhie A, Grant RC, Herman M, Wang L, Knox JJ, Bhat M. Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Future Oncol 2022. [PMID: 35287469 DOI: 10.2217/fon-2021-1635] [Reference Citation Analysis]
6 Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Letters 2020;470:8-17. [DOI: 10.1016/j.canlet.2019.12.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 43] [Article Influence: 16.5] [Reference Citation Analysis]
7 Geissler EK, Schlitt HJ. Can Mycophenolic Acid-based Immunosuppression Benefit Liver Transplant Patients With HCC? Transplantation 2019;103:873-4. [PMID: 30720687 DOI: 10.1097/TP.0000000000002648] [Reference Citation Analysis]
8 Hendrickson PG, Olson M, Luetkens T, Weston S, Han T, Atanackovic D, Fine GC. The promise of adoptive cellular immunotherapies in hepatocellular carcinoma.Oncoimmunology. 2020;9:1673129. [PMID: 32002284 DOI: 10.1080/2162402X.2019.1673129] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Fan J, Han J, Li J, Gu A, Yin D, Song F, Wang L, Yi Y. The expression and function of immunoglobulin-like transcript 4 in dendritic cells from patients with hepatocellular carcinoma. Hum Immunol. 2020;81:714-725. [PMID: 33228921 DOI: 10.1016/j.humimm.2020.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Mocan T, Sparchez Z, Craciun R, Bora CN, Leucuta DC. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clin Transl Oncol 2019;21:702-12. [PMID: 30387047 DOI: 10.1007/s12094-018-1975-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
11 Hage C, Hoves S, Ashoff M, Schandl V, Hört S, Rieder N, Heichinger C, Berrera M, Ries CH, Kiessling F, Pöschinger T. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy. PLoS One 2019;14:e0219517. [PMID: 31291357 DOI: 10.1371/journal.pone.0219517] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lake CM, Voss K, Bauman BM, Pohida K, Jiang T, Dveksler G, Snow AL. TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1. Cell Death Dis 2021;12:400. [PMID: 33854046 DOI: 10.1038/s41419-021-03689-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Bowen SR, Hippe DS, Chaovalitwongse WA, Duan C, Thammasorn P, Liu X, Miyaoka RS, Vesselle HJ, Kinahan PE, Rengan R, Zeng J. Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging. Clin Cancer Res 2019;25:5027-37. [PMID: 31142507 DOI: 10.1158/1078-0432.CCR-18-3908] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
14 Leineweber CG, Pietzner A, Zhang IW, Blessin UB, Rothe M, Schott E, Schebb NH, Weylandt KH. Assessment of the Effect of Sorafenib on Omega-6 and Omega-3 Epoxyeicosanoid Formation in Patients with Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1875. [PMID: 32182938 DOI: 10.3390/ijms21051875] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
15 Sweed D, Sultan MM, Mosbeh A, Fayed YA, Abdelsameea E, Ehsan NA, Abdel-Rahman MH, Waked I. Lymphoepithelioma-like Hepatocellular Carcinoma: a Case Report and Review of Literature. J Gastrointest Cancer 2021. [PMID: 34813031 DOI: 10.1007/s12029-021-00757-0] [Reference Citation Analysis]
16 Kang S, Bai X, Chen S, Song Y, Liu L. The potential combinational immunotherapiesfor treatment of hepatocellular carcinoma. J Interv Med 2019;2:47-51. [PMID: 34805871 DOI: 10.1016/j.jimed.2019.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]